A Retrospective Cohort Study of Transgender Adolescents' Gender-Affirming Hormone Discontinuation

    January 2025 in “ Journal of Adolescent Health ”
    Elizabeth R. Boskey, Kathryn L Scheffey, Sarah Pilcher, Ellis P. Barerra, Kerry McGregor, Jeremi M. Carswell, Jared Douglas Kant, Jessica Kremen
    TLDR Most transgender adolescents continued hormone treatment, with few stopping due to reasons other than returning to their birth gender.
    This retrospective cohort study examined the discontinuation of gender-affirming hormones (GAH) among transgender adolescents. Out of 1,050 eligible individuals, 93% continued GAH at last contact, while 4% discontinued without restarting. Only 0.5% reidentified with their birth-assigned gender. The study concludes that persistent discontinuation is rare and often due to achieving gender expression goals or access issues, rather than detransitioning. Future research should focus on understanding the reasons for discontinuation without assuming detransition or regret.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results